Skip to main content
SpringerLink
Log in

Prevention of Prostate Cancer

  • Chapter
  • First Online:
Fundamentals of Cancer Prevention

  • 1671 Accesses

Abstract

According to the American Cancer Society, prostate cancer is the second most common cause of cancer-related mortality for US men. A continuing research challenge is to improve diagnosis (especially the ability to detect uncommon aggressive cancers) and improve chemoprevention (through nutrition and lifestyle factors). The chapter highlights the growing importance of secondary prevention since prostate cancer is an indolent, slow growing tumor; preventing early tumor progression or eradicating early bone metastases may cure the disease. Considerations of the known etiology and biology of prostate cancer are presented as well as the strengths and limitations of current diagnostic and prognostic factors and specific interventions that have been tested. Lastly, promising avenues for secondary prevention strategies are presented based upon current knowledge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • ACS (2012) Cancer facts & figures 2012. American Cancer Society, Atlanta

    Google Scholar 

  • Affolter M, Caussinus E (2008) Tracheal branching morphogenesis in Drosophila: new insights into cell behaviour and organ architecture. Development 135(12):2055–2064

    PubMed  CAS  Google Scholar 

  • Aggarwal B (2008) Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther 7:1436–1440

    PubMed  CAS  Google Scholar 

  • Aggarwal B, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30:85–94

    PubMed  CAS  Google Scholar 

  • Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69:195–206

    PubMed  CAS  Google Scholar 

  • Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147(1):89–104

    PubMed  CAS  Google Scholar 

  • Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang W, Shikany JM, Hayes RB (2008) Serum vitamin D concentration and prostate: cancer risk: a nested case – control study. J Natl Cancer Inst 100(11):796–804

    PubMed  CAS  Google Scholar 

  • Aigner F, Mitterberger M, Rehder P, Pallwein L, Junker D, Horninger W, Frauscher F (2010) Status of transrectal ultrasound imaging of the prostate. J Endourol 24(5):685–691

    PubMed  Google Scholar 

  • Akin O, Hricak H (2007) Imaging of prostate cancer. Radiol Clin North Am 45(1):207–222

    PubMed  Google Scholar 

  • Albertsen PC, Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17):2095–2101

    PubMed  CAS  Google Scholar 

  • Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP (2012) Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73(3):328–335

    PubMed  Google Scholar 

  • Allen GW, Howard AR, Jarrard DF, Ritter MA (2007) Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 110(7):1405–1416

    PubMed  Google Scholar 

  • Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2010) SEER cancer statistics review, 1975–2007. National Cancer Institute, Bethesda

    Google Scholar 

  • Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818

    PubMed  CAS  Google Scholar 

  • Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202

    PubMed  CAS  Google Scholar 

  • Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27(3):253–263

    PubMed  CAS  Google Scholar 

  • Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53(2):171–184

    PubMed  CAS  Google Scholar 

  • Bae MK, Kim S, Jeong JW, Lee YM, Kim HS, Kim SR, Yun I, Bae SK, Kim KW (2006) Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15:1557–1562

    PubMed  CAS  Google Scholar 

  • Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217

    PubMed  CAS  Google Scholar 

  • Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685–689

    PubMed  CAS  Google Scholar 

  • Bartolozzi C, Menchi I, Lencioni R, Serni S, Lapini A, Barbanti G, Bozza A, Amorosi A, Manganelli A, Carini M (1996) Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur Radiol 6(3):339–345

    PubMed  CAS  Google Scholar 

  • Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P, Tyrol G, Prostate Cancer Screening (2008) Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101(7):809–816

    PubMed  CAS  Google Scholar 

  • Basnet P, Skalko-Basnet N (2011) Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16:4567–4598

    PubMed  CAS  Google Scholar 

  • Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F (2009) Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55(6):1321–1330

    PubMed  Google Scholar 

  • Beaver L, Williams DE, Dashwood RH, Ho E (2012) Chemoprevention of prostate cancer with cruciferous vegetables: role of epigenetics. In: Shankar S, Srivastava RK (eds) Nutrition, diet and cancer. Springer, New York

    Google Scholar 

  • Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T (2006) Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat 97(1):91–96

    PubMed  CAS  Google Scholar 

  • Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W (2010) 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254(3):925–933

    PubMed  Google Scholar 

  • Bello-DeOcampo D, Tindall DJ (2003) TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets 4(3):197–207

    PubMed  CAS  Google Scholar 

  • Beltowski J, Wójcicka G, Jamroz-Wizniewska A (2009) Adverse effects of statins – mechanisms and consequences. Curr Drug Saf 4(3):209–228

    PubMed  CAS  Google Scholar 

  • Belvindrah R, Hankel S, Walker J, Patton BL, Muller U (2007) Beta1 integrins control the formation of cell chains in the adult rostral migratory stream. J Neurosci 27(10):2704–2717

    PubMed  CAS  Google Scholar 

  • Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66(2):1234–1240

    PubMed  CAS  Google Scholar 

  • Bloch BN, Furman-Haran E, Helbich TH, Lenkinski RE, Degani H, Kratzik C, Susani M, Haitel A, Jaromi S, Ngo L, Rofsky NM (2007) Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging – initial results. Radiology 245(1):176–185

    PubMed  Google Scholar 

  • Bonkhoff H, Stein U, Remberger K (1993) Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol 24(3):243–248

    PubMed  CAS  Google Scholar 

  • Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL (2000) Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 163(1):158–162

    PubMed  CAS  Google Scholar 

  • Bouchelouche K, Oehr P (2008) Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 179(1):34–45

    PubMed  CAS  Google Scholar 

  • Brawley OW (2012) Prostate cancer epidemiology in the United States. World J Urol 30(2):195–200

    PubMed  Google Scholar 

  • Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, Oyen R, Ameye F, Bogaerts K, Haustermans K, Van Poppel H (2011) Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 60(1):125–130

    PubMed  Google Scholar 

  • Burton A, Tilling KM, Holly JM, Hamdy FC, Rowlands ME, Donovan JL, Martin RM (2010) Metabolic imbalance and prostate cancer progression. Int J Mol Epidemiol Genet 1(4):248–271

    PubMed  CAS  Google Scholar 

  • Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41(5):619–624

    PubMed  CAS  Google Scholar 

  • Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, Teixeira MR (2006) TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8(10):826–832

    PubMed  CAS  Google Scholar 

  • Cetin K, Beebe-Dimmer JL, Fryzek JP, Markus R, Carducci MA (2010) Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology 75(6):1396–1404

    PubMed  Google Scholar 

  • Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572

    PubMed  CAS  Google Scholar 

  • Chang JJ, Shinohara K, Bhargava V, Presti JC Jr (1998) Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 160(6 Pt 1):2111–2114

    PubMed  CAS  Google Scholar 

  • Chauhan S, Kunz S, Davis K, Roberts J, Martin G, Demetriou MC, Sroka TC, Cress AE, Miesfeld RL (2004) Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling. J Biol Chem 279(2):937–944

    PubMed  CAS  Google Scholar 

  • Chen MC, Huang CY, Hsu SL, Lin E, Ku CT, Lin H, Chen CM (2012) Retinoic acid induces apoptosis of prostate cancer DU145 cells through Cdk5 overactivation. Evid Based Complement Altern Med 2012

    Google Scholar 

  • Chou R, Dana T, Bougatsos C, Fu R, Blazina I, Gleitsmann K, Rugge JB (2011) Treatments for localized prostate cancer: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Agency for Healthcare Research and Quality, Rockville

    Google Scholar 

  • Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276(24):1957–1963

    PubMed  CAS  Google Scholar 

  • Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165–176

    PubMed  CAS  Google Scholar 

  • Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249s

    PubMed  Google Scholar 

  • Conti G, La Torre G, Cicalese V, Micheletti G, Ludovico MG, Vestita GD, Cottonaro G, Introini C, Cecchi M (2008) Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. Arch Ital Urol Androl 80(2):59–64

    PubMed  Google Scholar 

  • Corcoran AT, Peele PB, Benoit RM (2010) Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology 76(3):703–707

    PubMed  Google Scholar 

  • Cornud F, Flam T, Chauveinc L, Hamida K, Chretien Y, Vieillefond A, Helenon O, Moreau JF (2002) Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 224(1):203–210

    PubMed  Google Scholar 

  • Crawford ED (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73(5 Suppl):S4–S10

    PubMed  Google Scholar 

  • Danen EH, van Muijen GN, van de Wiel-van Kemenade E, Jansen KF, Ruiter DJ, Figdor CG (1993) Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int J Cancer 54(2):315–321

    PubMed  CAS  Google Scholar 

  • David E, Blanchard F, Heymann MF, De Pinieux G, Gouin F, Rédini F, Heymann D (2011) The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma 2011, 8 pages. doi:10.1155/2011/932451

  • de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44(3):331–335

    PubMed  Google Scholar 

  • Delpassand ES, Garcia JR, Bhadkamkar V, Podoloff DA (1995) Value of SPECT imaging of the thoracolumbar spine in cancer patients. Clin Nucl Med 20(12):1047–1051

    PubMed  CAS  Google Scholar 

  • Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596–4599

    PubMed  CAS  Google Scholar 

  • Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnaiyan AM, Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT, Scherr DS, Sanda MA, Bartsch G, Lee C, Klocker H, Rubin MA (2012) Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A 109(17):6686–6691

    PubMed  CAS  Google Scholar 

  • Dorai T, Gehani N, Katz A (2000) Therapeutic potential of curcumin in human prostate cancer – I. Curcumin induces apoptosis in both Curcumin inhibits AR through Wnt/b-catenin signaling androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis 3:84–93

    PubMed  CAS  Google Scholar 

  • Downes CP, Bennett D, McConnachie G, Leslie NR, Pass I, MacPhee C, Patel L, Gray A (2001) Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans 29(Pt 6):846–851

    PubMed  CAS  Google Scholar 

  • Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC, F. t. Nutritional Prevention of Cancer Study Group (2003) Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95(19):1477–1481

    PubMed  CAS  Google Scholar 

  • Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155(3):994–998

    PubMed  CAS  Google Scholar 

  • Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185(3):869–875

    PubMed  Google Scholar 

  • Ellegala DB, Leong-Poi H, Carpenter JE, Klibanov AL, Kaul S, Shaffrey ME, Sklenar J, Lindner JR (2003) Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 108(3):336–341

    PubMed  Google Scholar 

  • Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO (2003) Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229(1):248–254

    PubMed  Google Scholar 

  • Epstein JI, Walsh P, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374

    PubMed  CAS  Google Scholar 

  • Epstein JI, Walsh PC, Carter HB (2001) Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 57(6):1112–1116

    PubMed  CAS  Google Scholar 

  • Evans HC, Goa KL (2003) Dutasteride. Drugs Aging 20(12):905–916; discussion 917–908

    PubMed  CAS  Google Scholar 

  • Even-Sapir E, Martin RH, Barnes DC, Pringle CR, Iles SE, Mitchell MJ (1993) Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology 187(1):193–198

    PubMed  CAS  Google Scholar 

  • Faloia E, Michetti G, De Robertis M, Luconi MP, Furlani G, Boscaro M (2012) Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012:476380

    Google Scholar 

  • Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG (2012) GCPII imaging and cancer. Curr Med Chem 19(9):1346–1359

    PubMed  CAS  Google Scholar 

  • Fosslien E (2000) Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30(1):3–21

    PubMed  CAS  Google Scholar 

  • Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 42(6):622–629

    PubMed  Google Scholar 

  • Friedrichs K, Ruiz P, Franke F, Gille I, Terpe HJ, Imhof BA (1995) High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 55(4):901–906

    PubMed  CAS  Google Scholar 

  • Georges-Labouesse E, Messaddeq N, Yehia G, Cadalbert L, Dierich A, Le Meur M (1996) Absence of integrin alpha 6 leads to epidermolysis bullosa and neonatal death in mice. Nat Genet 13(3):370–373

    PubMed  CAS  Google Scholar 

  • Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ (1995) Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 55(17):3726–3731

    PubMed  CAS  Google Scholar 

  • Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15:1977–1983

    PubMed  Google Scholar 

  • Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239–243

    PubMed  CAS  Google Scholar 

  • Gray N (2012) Daily dose of red wine compound backed for cancer fight. NutraIngredient.com. 15 Dec 2012

  • Grover S, Lowensteyn I, Hajek D, Trachtenberg J, Coupal L, Marchand S (2006) Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? J Urol 175(3 Pt 1):934–938; discussion 938

    PubMed  CAS  Google Scholar 

  • Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695

    PubMed  CAS  Google Scholar 

  • Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (1999) Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma. Prostate 42(1):73–78

    Google Scholar 

  • Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, Scherr P, Schmid DT, Graf N, von Weymarn CA, Willemse EM, Binkert CA (2010) Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 39(4):333–343

    PubMed  Google Scholar 

  • Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G (2008) The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 15(1):3866–3871

    PubMed  Google Scholar 

  • Hallstrom TM, Laiho M (2008) Genetic changes and DNA damage responses in the prostate. Prostate 68(8):902–918

    PubMed  Google Scholar 

  • Hamilton RJ, Freedland SJ (2011) 5-alpha reductase inhibitors and prostate cancer prevention: where do we turn now? BMC Med 9:105

    PubMed  CAS  Google Scholar 

  • Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB (2009) Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22(8):1083–1093

    PubMed  CAS  Google Scholar 

  • Hangan D, Morris VL, Boeters L, von Ballestrem C, Uniyal S, Chan BM (1997) An epitope on VLA-6 (alpha6beta1) integrin involved in migration but not adhesion is required for extravasation of murine melanoma B16F1 cells in liver. Cancer Res 57(17):3812–3817

    PubMed  CAS  Google Scholar 

  • Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348(25):2491–2499

    PubMed  Google Scholar 

  • Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M (2009) A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 9:14

    PubMed  Google Scholar 

  • Haustermans KM, Hofland I, Van Poppel H, Oyen R, Van de Voorde W, Begg AC, Fowler JF (1997) Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37(5):1067–1070

    PubMed  CAS  Google Scholar 

  • Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, Crowell JA, Levine BS, Kong AN (2005) Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299–2314

    PubMed  CAS  Google Scholar 

  • Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ (2009) Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 101(11):1833–1838

    PubMed  CAS  Google Scholar 

  • Hofer M, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE et al (2004) The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 64:825–829

    PubMed  CAS  Google Scholar 

  • Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395

    PubMed  CAS  Google Scholar 

  • Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG (2005) Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol 20(4):1339–1349

    PubMed  CAS  Google Scholar 

  • Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58–68

    PubMed  Google Scholar 

  • Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S (1998) Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 159(3):915–919

    PubMed  CAS  Google Scholar 

  • Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S (2001) Endorectal magnetic resonance imaging of prostatic cancer: comparison between fat-suppressed T2-weighted fast spin echo and three-dimensional dual-echo, steady-state sequences. Eur Radiol 11(2):236–241

    PubMed  CAS  Google Scholar 

  • Jacobs SC (1983) Spread of prostatic cancer to bone. Urology 21(4):337–344

    PubMed  CAS  Google Scholar 

  • Jadvar H (2011) Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 52(1):81–89

    PubMed  Google Scholar 

  • Jang M, Cai L, Udeani GO, Slowing KV et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297):218–220

    PubMed  CAS  Google Scholar 

  • Jin G, Sun J, Liu W, Zhang Z, Chu LW, Kim ST, Sun J, Feng J, Duggan D, Carpten JD, Wiklund F, Gronberg H, Isaacs WB, Zheng SL, Xu J (2011) Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis 32(7):1057–1062

    PubMed  CAS  Google Scholar 

  • Jones JS (2007) Saturation biopsy for detecting and characterizing prostate cancer. BJU Int 99(6):1340–1344

    PubMed  Google Scholar 

  • Kai L, Samuel SK, Levenson AS (2010) Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 126:1538–1548

    PubMed  CAS  Google Scholar 

  • Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549

    PubMed  CAS  Google Scholar 

  • Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr (2009) PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 73(5):935–939

    PubMed  Google Scholar 

  • Karunagaran D, Rashmi R, Kumar TR (2005) Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets 5:117–129

    PubMed  CAS  Google Scholar 

  • Kelloff G, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC (1999) Chemoprevention of prostate cancer: concepts and strategies. Eur Urol 35(5–6):342–350

    PubMed  CAS  Google Scholar 

  • Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA (2000) Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2):467S–471S

    PubMed  CAS  Google Scholar 

  • Kelsey L, Katoch P, Johnson KE, Batra SK, Mehta PP (2012) Retinoids regulate the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells. PLoS One 7(4):e32846

    PubMed  CAS  Google Scholar 

  • Khan N, Adhami VM, Mukhtar H (2008) Apoptosis by dietary agents for prevention and treatment of cancer. Biochem Pharmacol 76(11):1333–1339

    PubMed  CAS  Google Scholar 

  • Khan N, Adhami VM, Mukhtar H (2009) Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer 61(6):836–841

    PubMed  CAS  Google Scholar 

  • Killian P, Kronski E, Michalik KM, Barbieri O, Astigiano S, Sommerhoff CP, Pfeffer U, NerlichAG, Bachmeier BE (2012) Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and −2. Carcinogenesis, 33(12):2507–2519. doi: 10.1093/carcin/bgs312

  • Kim CK, Choi D, Park BK, Kwon GY, Lim HK (2008) Diffusion-weighted MR imaging for the evaluation of seminal vesicle invasion in prostate cancer: initial results. J Magn Reson Imaging 28(4):963–969

    PubMed  Google Scholar 

  • Kiuchi F, Goto Y, Sugimoto N, Akao N, Kondo K, Tsuda Y (1993) Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem Pharm Bull 41:1640–1643

    PubMed  CAS  Google Scholar 

  • Kiviharju-af Hallstrom TM, Jaamaa S, Monkkonen M, Peltonen K, Andersson LC, Medema RH, Peehl DM, Laiho M (2007) Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A 104(17):7211–7216

    PubMed  CAS  Google Scholar 

  • Klein EA, Thompson IM Jr, Tangen CM et al (2011) Vitamin e and the risk of prostate cancer: the selenium and vitamin e cancer prevention trial (select). JAMA 306(14):1549–1556

    PubMed  CAS  Google Scholar 

  • Kloepper JE, Tiede S, Brinckmann J, Reinhardt DP, Faessler R, Meyer W, Paus R (2008) Immunophenotyping of the human bulge region: the quest to define useful in situ markers for human epithelial hair follicle stem cells and their niche. Exp Dermatol 17(7):592–609

    PubMed  Google Scholar 

  • Klotz L (2012) Cancer overdiagnosis and overtreatment. Curr Opin Urol 22(3):203–209

    PubMed  Google Scholar 

  • Kraft T, Parisotto D, Schempp C, Efferth T (2009) Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit Rev Food Sci Nutr 49(9):782–799

    PubMed  CAS  Google Scholar 

  • Krishnan AV, Feldman D (2011) Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51:311–336

    PubMed  CAS  Google Scholar 

  • Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE (2006) Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175(2):505–509

    PubMed  Google Scholar 

  • Kuttan G, Kumar KBH, Guruvayoorappan C, Kuttan R (2007) Antitumor, anti-invasion, and anti-metastatic effects of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, a special issue of Adv Exp Med Biol 595: 173–184

    Google Scholar 

  • Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR (2007) A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 20(4):467–473

    PubMed  CAS  Google Scholar 

  • Lattouf J-B, Saad F (2007) Preservation of bone health in prostate cancer. Curr Opin Support Palliat Care 1(3):192–197

    PubMed  Google Scholar 

  • Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othee BJ, Therasse P, Vande Berg B, Tombal B (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25(22):3281–3287

    PubMed  Google Scholar 

  • Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172(7):973–981

    PubMed  CAS  Google Scholar 

  • Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, Prockop DJ (2009) The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113(4):816–826

    PubMed  CAS  Google Scholar 

  • Li H, Stampfer MJ, Hollis JBW, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103

    PubMed  Google Scholar 

  • Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37(9):1618–1625

    PubMed  CAS  Google Scholar 

  • Lin D, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Grönberg H, Stanford JL (2011) Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 20(9):1928–1936

    PubMed  CAS  Google Scholar 

  • Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1):39–51

    PubMed  CAS  Google Scholar 

  • Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57(1):108–111

    PubMed  CAS  Google Scholar 

  • Liu W, Sun J, Li G, Zhu Y, Zhang S, Kim ST, Sun J, Wiklund F, Wiley K, Isaacs SD, Stattin P, Xu J, Duggan D, Carpten JD, Isaacs WB, Gronberg H, Zheng SL, Chang BL (2009) Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res 69(6):2176–2179

    PubMed  CAS  Google Scholar 

  • Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA, Thompson IM (2008) Pathologic characteristics of cancers detected in the prostate cancer prevention trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res 1(3):167–173

    CAS  Google Scholar 

  • Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE (1996) Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 88(3–4):166–173

    PubMed  CAS  Google Scholar 

  • Makarov DV, Loeb S, Getzenberg RH, Partin AW (2009) Biomarkers for prostate cancer. Annu Rev Med 60:139–151

    PubMed  CAS  Google Scholar 

  • Marchesi F, Piemonti L, Mantovani A, Allavena P (2010) Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev 21(1):77–82

    PubMed  CAS  Google Scholar 

  • Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, Bertaccini A, Manferrari F, Castellucci P, Fanti S, Canini R, Grigioni WF, D’Errico Grigioni A (2006) 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 176(3):954–960; discussion 960

    PubMed  CAS  Google Scholar 

  • Mastro AM, Vogler EA (2009) A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res 69(10):4097–4100

    PubMed  CAS  Google Scholar 

  • Matsuyama M, Yoshimura R (2008) The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics 2(4):725–732

    PubMed  CAS  Google Scholar 

  • Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM (2008) Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68(10):3584–3590

    PubMed  CAS  Google Scholar 

  • Moore SC, Peters TM, Ahn J, Park Y, Schatzkin A, Albanes D, Hollenbeck A, Leitzmann MF (2009) Age-specific physical activity and prostate cancer risk among white men and black men. Cancer 115(21):5060–5070

    PubMed  Google Scholar 

  • Nacusi LP, Tindall DJ (2011) Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat Rev Urol 8(7):378–384

    PubMed  CAS  Google Scholar 

  • Nagle RB, Cress AE (2011) Metastasis update: human prostate carcinoma invasion via tubulogenesis. Prostate Cancer 2011:249290

    PubMed  Google Scholar 

  • Naik R, Mujumdar AM, Ghaskadbi S (2004) Protection of liver cells from ethanol cytotoxicity by curcumin in liver slice culture in vitro. J Ethnopharmacol 95(1):31–37

    PubMed  CAS  Google Scholar 

  • Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S et al (2002) Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 21:825–830

    PubMed  CAS  Google Scholar 

  • Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA, Seth A (2007) Expression of TMPRSS2: ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6(1):40–45

    PubMed  CAS  Google Scholar 

  • Nayyar R, Sharma N, Gupta NP (2010) Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol Int 84(2):159–163

    PubMed  CAS  Google Scholar 

  • Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C (1997) The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50(4):562–566

    PubMed  CAS  Google Scholar 

  • Norskov MS, Frikke-Schmidt R, Bojesen SE, Nordestgaard BG, Loft S, Tybjaerg-Hansen A (2011) Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population. Pharmacogenomics J 11(4):292–299

    PubMed  CAS  Google Scholar 

  • Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE (2011) Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 333(6039):218–221

    PubMed  CAS  Google Scholar 

  • Nozaki T, Yasuda K, Akashi T, Fuse H (2008) Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer. Int J Urol 15(6):516–519

    PubMed  Google Scholar 

  • Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM (2002) Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43(1):46–55

    PubMed  Google Scholar 

  • Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G (2006) Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 164(4):376–384

    PubMed  Google Scholar 

  • Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC (1993) The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269(1):57–60

    PubMed  CAS  Google Scholar 

  • Orsini N, Bellocco R, Bottai M, Pagano M, Andersson S-O, Johansson J-E, Giovannucci E, Wolk A (2009) A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer 101:1932–1938

    PubMed  CAS  Google Scholar 

  • Parekh DJ (2011) Prostate cancer prevention with 5 alpha-reductase inhibitors. Recent Results Cancer Res 188:109–114

    PubMed  CAS  Google Scholar 

  • Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE (2007) Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp Cell Res 313(6):1080–1089

    PubMed  CAS  Google Scholar 

  • Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66(17):8337–8341

    PubMed  CAS  Google Scholar 

  • Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31(6):882–888

    PubMed  Google Scholar 

  • Perrotti M, Kaufman RP Jr, Jennings TA, Thaler HT, Soloway SM, Rifkin MD, Fisher HA (1996) Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol 156(1):106–109

    PubMed  CAS  Google Scholar 

  • Pezzuto J (2008) Resveratrol as an inhibitor of carcinogenesis. Pharm Biol 46(7–8):443–573

    CAS  Google Scholar 

  • Pienta K, McGregor N, Axelrod R, Axelrod DE (2008) Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 1(4):158–164

    PubMed  Google Scholar 

  • Pinto F, Totaro A, Calarco A, Sacco E, Volpe A, Racioppi M, D’Addessi A, Gulino G, Bassi P (2011) Imaging in prostate cancer diagnosis: present role and future perspectives. Urol Int 86(4):373–382

    PubMed  Google Scholar 

  • Pinto F, Totaro A, Palermo G, Calarco A, Sacco E, D’Addessi A, Racioppi M, Valentini A, Gui B, Bassi P (2012) Imaging in prostate cancer staging: present role and future perspectives. Urol Int 88(2):125–136

    PubMed  Google Scholar 

  • Piper J, Singhal SS, Salameh MS, Torman RT, Awasthi YC, Awasthi S (1998) Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 30:445–456

    PubMed  CAS  Google Scholar 

  • Plummer S, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA (2001) Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 10:1295–1299

    PubMed  CAS  Google Scholar 

  • Ports MO, Nagle RB, Pond GD, Cress AE (2009) Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res 69(12):5007–5014

    PubMed  CAS  Google Scholar 

  • Pouliot F, Johnson M, Wu L (2009) Non-invasive molecular imaging of prostate cancer lymph node metastasis. Trends Mol Med 15(6):254–262

    PubMed  CAS  Google Scholar 

  • Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, Svolgaard N, Ogren M, Vach W, Hoilund-Carlsen PF, Geertsen U, Walter S (2010) [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 106(5):639–643; discussion 644

    PubMed  Google Scholar 

  • Presti JC Jr, Hricak H, Narayan PA, Shinohara K, White S, Carroll PR (1996) Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol 166(1):103–108

    PubMed  Google Scholar 

  • Presti JC Jr, Chang JJ, Bhargava V, Shinohara K (2000) The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163(1):163–166; discussion 166–167

    PubMed  Google Scholar 

  • Qian H, Georges-Labouesse E, Nystrom A, Domogatskaya A, Tryggvason K, Jacobsen SE, Ekblom M (2007) Distinct roles of integrins alpha6 and alpha4 in homing of fetal liver hematopoietic stem and progenitor cells. Blood 110(7):2399–2407

    PubMed  CAS  Google Scholar 

  • Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR (1998) Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 159(4):1247–1250

    PubMed  CAS  Google Scholar 

  • Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG (2007) Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60(11):1238–1243

    PubMed  CAS  Google Scholar 

  • Rao C (2007) Regulation of COX and LOX by curcumin. In: Aggarwal BB, Surh YJ, Shishodia S (eds) Molecular targets and therapeutic uses of curcumin in health and disease. Springer, New York

    Google Scholar 

  • Ravindran J, Sahdeo Prasad S, Aggarwal BB (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11(3):495–510

    PubMed  CAS  Google Scholar 

  • Ravizzini G, Turkbey B, Kurdziel K, Choyke PL (2009) New horizons in prostate cancer imaging. Eur J Radiol 70(2):212–226

    PubMed  Google Scholar 

  • Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM (2008) Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 1(3):174–181

    CAS  Google Scholar 

  • Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC, Marshall JR (2004) A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18(1):69–74

    PubMed  CAS  Google Scholar 

  • Reischauer C, Froehlich JM, Koh DM, Graf N, Padevit C, John H, Binkert CA, Boesiger P, Gutzeit A (2010) Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps – initial observations. Radiology 257(2):523–531

    PubMed  Google Scholar 

  • Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M (2008) Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76(11):1340–1351

    PubMed  CAS  Google Scholar 

  • Rinnab L, Blumstein NM, Mottaghy FM, Hautmann RE, Kufer R, Hohl K, Reske SN (2007) 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 99(6):1421–1426

    PubMed  CAS  Google Scholar 

  • Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE (2007) Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study: II. Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16(1):63–69

    PubMed  Google Scholar 

  • Rorvik J, Halvorsen OJ, Albrektsen G, Ersland L, Daehlin L, Haukaas S (1999) MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy. Eur Radiol 9(1):29–34

    PubMed  CAS  Google Scholar 

  • Rothwell P, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 377:31–41

    PubMed  CAS  Google Scholar 

  • Rothwell P, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379:1591–1601

    PubMed  CAS  Google Scholar 

  • Sala E, Akin O, Moskowitz CS, Eisenberg HF, Kuroiwa K, Ishill NM, Rajashanker B, Scardino PT, Hricak H (2006) Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 238(3):929–937

    PubMed  Google Scholar 

  • Salvioli S, Sikora E, Cooper EL, Franceschi C (2007) Curcumin in cell death processes: a challenge for CAM of age-related pathologies. Evid Based Complement Alternat Med 4(2):181–190

    PubMed  CAS  Google Scholar 

  • Sauvain JL, Palascak P, Bourscheid D, Chabi C, Atassi A, Bremon JM, Palascak R (2003) Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. Eur Urol 44(1):21–30; discussion 30–21

    PubMed  CAS  Google Scholar 

  • Scher H, Pantel K (2009) Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out? J Clin Oncol 27(10):1531–1533

    PubMed  Google Scholar 

  • Scher HI, Morris MJ, Basch E, Heller G (2011) End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 29(27):3695–3704

    PubMed  Google Scholar 

  • Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, Franceschelli A, Sanguedolce F, Bertaccini A, Farsad M, Giovacchini G, Fanti S, Grigioni WF, Fazio F, Montorsi F, Rigatti P, Martorana G (2008) 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54(2):392–401

    PubMed  Google Scholar 

  • Schiebler ML, Yankaskas BC, Tempany C, Spritzer CE, Rifkin MD, Pollack HM, Holtz P, Zerhouni EA (1992) MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. AJR Am J Roentgenol 158(3):559–562; discussion 563–554

    PubMed  CAS  Google Scholar 

  • Schoder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34(4):274–292

    PubMed  Google Scholar 

  • Schroder FH (2011) Stratifying risk – the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 365(21):1953–1955

    PubMed  Google Scholar 

  • Sciarra A, Panebianco V, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Mariotti G, Passariello R, Gentile V (2011) Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol 29(1):12–20

    PubMed  Google Scholar 

  • SEER (2012) Prostate Cancer (Chapter 23): Trends in SEER incidence and U.S. mortality using the join point regression program. In: Howlader N, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER cancer statistics review, 1975–2009. National Cancer Institute, Bethesda

    Google Scholar 

  • Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser A (2009) Functional magnetic resonance imaging in prostate cancer. Eur Urol 55(4):801–814

    PubMed  CAS  Google Scholar 

  • Shankar S, Srivastava RK (2012) Curcumin: structure, biology and clinical applications. In: Shankar S, Srivastava RK (eds) Nutrition, diet and cancer. Springer, New York

    Google Scholar 

  • Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM (2007) Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25(4):349–355

    PubMed  CAS  Google Scholar 

  • Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, Manson MM, Marnett LJ, Steward WP, Gescher A (2001) Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 7:1452–1458

    PubMed  CAS  Google Scholar 

  • Sharma RA, Gescher AJ, Steward WP (2005) Curcumin: the story so far. Eur J Cancer 41:1955–1968

    PubMed  CAS  Google Scholar 

  • Shen L, Ji H-F (2012a) Low stability remedies the low bioavailability of curcumin. Trends Mol Med 18(7):363–364

    CAS  Google Scholar 

  • Shen L, Ji H-F (2012b) The pharmacology of curcumin: is it the degradation products? Trends Mol Med 18(3):135–192

    Google Scholar 

  • Sheng S (2001) The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20(3–4):287–296

    PubMed  CAS  Google Scholar 

  • Shi Q, Shih CC, Lee KH (2009) Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. Anticancer Agents Med Chem 9:904–991

    PubMed  CAS  Google Scholar 

  • Singha P, Matanheliab SS, Martin FL (2008) A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 44:928–936

    Google Scholar 

  • Sklar LA, Edwards BS, Graves SW, Nolan JP, Prossnitz ER (2002) Flow cytometric analysis of ligand-receptor interactions and molecular assemblies. Annu Rev Biophys Biomol Struct 31(1):97–119

    PubMed  CAS  Google Scholar 

  • Sloane BF, Sameni M, Podgorski I, Cavallo-Medved D, Moin K (2006) Functional imaging of tumor proteolysis. Annu Rev Pharmacol Toxicol 46(1):301–315

    PubMed  CAS  Google Scholar 

  • Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H (2001) American Cancer Society Guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers: ALSO: update 2001—testing for early lung cancer detection. CA Cancer J Clin 51(1):38–75

    PubMed  CAS  Google Scholar 

  • Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31:412–419

    PubMed  CAS  Google Scholar 

  • Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW (2010) A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19(5):1193–1200

    PubMed  Google Scholar 

  • Sonnenberg A, Gehlsen KR, Aumailley M, Timpl R (1991) Isolation of alpha 6 beta 1 integrins from platelets and adherent cells by affinity chromatography on mouse laminin fragment E8 and human laminin pepsin fragment. Exp Cell Res 197(2):234–244

    PubMed  CAS  Google Scholar 

  • Squire JA (2009) TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 41(5):509–510

    PubMed  CAS  Google Scholar 

  • Sroka IC, Pond GD, Nagle RB, Porreca F, King T, Pestano G, Futscher BW, Gard JM, Riley J, Cress AE (2009) Human cell surface receptors as molecular imaging candidates for metastatic prostate cancer. Open Prostate Cancer J 2:59–66

    CAS  Google Scholar 

  • Stattin P, Lumme S, Tenkanen L et al (2004) High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108

    Google Scholar 

  • Steeg PS, Theodorescu D (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5(4):206–219

    PubMed  CAS  Google Scholar 

  • Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51(1):222–226

    PubMed  CAS  Google Scholar 

  • Stephan C, Cammann H, Meyer HA, Lein M, Jung K (2007) PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 249(1):18–29

    PubMed  CAS  Google Scholar 

  • Stephan C, Rittenhouse H, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K (2009) New markers and multivariate models for prostate cancer detection. Anticancer Res 29(7):2589–2600

    PubMed  CAS  Google Scholar 

  • Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF, Haese A, Klutmann S, Kollermann J, Sauter G, Mester J, Mikecz P, Fisch M, Huland H, Graefen M, Salomon G (2010) [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 46(2):449–455

    PubMed  CAS  Google Scholar 

  • Stewart CS, Leibovich BC, Weaver AL, Lieber MM (2001) Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166(1):86–91; discussion 91–82

    PubMed  CAS  Google Scholar 

  • Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439(7079):993–997

    PubMed  CAS  Google Scholar 

  • Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, Medina D, Fässler R, Thiery JP, Glukhova MA (2008) β1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 10(6):716–722

    PubMed  CAS  Google Scholar 

  • Thanigasalam R, Mancuso P, Tsao K, Rashid P (2009) Prostate-specific antigen velocity (PSAV): a practical role for PSA? ANZ J Surg 79(10):703–706

    PubMed  Google Scholar 

  • Thompson IM (2006) Defining high risk prostate cancer—where do we set the bar? A translational science approach to risk stratification. J Urol 176(6):S21–S24

    PubMed  Google Scholar 

  • Thompson IM, Ankerst DP (2007) Prostate-specific antigen in the early detection of prostate cancer. CMAJ 176(13):1853–1858

    PubMed  Google Scholar 

  • Thompson IM, Ankerst DP (2012) Editorial for special issue on epidemiology and prevention of prostate cancer. World J Urol 30(2):129–130

    PubMed  Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224

    PubMed  CAS  Google Scholar 

  • Thurairaja R, McFarlane J, Traill Z, Persad R (2004) State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 94(3):268–271

    PubMed  Google Scholar 

  • Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648

    PubMed  CAS  Google Scholar 

  • Tsui K, Feng TH, Lin CM, Chang PL, Juang HH (2008) Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl 29:661–668

    PubMed  CAS  Google Scholar 

  • Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, Fuchs E (2004) Defining the epithelial stem cell niche in skin. Science 303(5656):359–363

    PubMed  CAS  Google Scholar 

  • Turkbey B, Albert PS, Kurdziel K, Choyke PL (2009a) Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 192(6):1471–1480

    PubMed  Google Scholar 

  • Turkbey B, Pinto PA, Choyke PL (2009b) Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 6(4):191–203

    PubMed  Google Scholar 

  • United States Preventive Services Task Force (2012) Screening for prostate cancer. From http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm

  • van Adelsberg J, Gann P, Ko AT, Damber J, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C (2007) The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 23(9):2063–2070

    PubMed  Google Scholar 

  • Vijayakumar S, Mehta RR, Boerner PS, Packianathan S, Mehta RG (2005) Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 11(5):362–373

    PubMed  CAS  Google Scholar 

  • Vitaglione P, Morisco F, Caporaso N, Fogliano V (2005) Dietary antioxidant compounds and liver health. Crit Rev Food Sci Nutr 44(7–8):575–586

    Google Scholar 

  • Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68(20):8516–8524

    PubMed  CAS  Google Scholar 

  • Weber G (1977) Enzymology of cancer cells (second of two parts). N Engl J Med 296(10):541–551

    PubMed  CAS  Google Scholar 

  • Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA (2009) Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27(10):1549–1556

    PubMed  Google Scholar 

  • Wels J, Kaplan RN, Rafii S, Lyden D (2008) Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 22(5):559–574

    PubMed  CAS  Google Scholar 

  • Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW et al (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87(9):652–661

    PubMed  CAS  Google Scholar 

  • Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, Kramer BS (2010) 5-alpha-reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int 106(10):1444–1451

    PubMed  CAS  Google Scholar 

  • Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA, American Cancer Society Prostate Cancer Advisory Committee (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60(2):70–98

    PubMed  Google Scholar 

  • Wright M, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Leitzmann MF (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675–684

    PubMed  Google Scholar 

  • Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL (2009) Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 182(6):2702–2707

    PubMed  Google Scholar 

  • Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, Zielenska M, Squire JA (2006) Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68 % of primary prostate cancer and 23 % of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169(2):128–137

    PubMed  CAS  Google Scholar 

  • Yoshimoto M, Ludkovski O, DeGrace D, Williams JL, Evans A, Sircar K, Bismar TA, Nuin P, Squire JA (2012) PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 51(2):149–160

    PubMed  CAS  Google Scholar 

  • Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S (2006) Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 34:109–115

    PubMed  CAS  Google Scholar 

  • Zaheer A, Cho SY, Pomper MG (2009) New agents and techniques for imaging prostate cancer. J Nucl Med 50(9):1387–1390

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Arizona Cancer Center, Tucson, AZ, USA

    Amit M. Algotar

  2. Departments of Surgery, Georgetown-Medstar University Hospital, Washington, DC, USA

    M. Suzanne Stratton

  3. University of Arizona, Tucson, AZ, USA

    William L. Harryman

  4. Cellular and Molecular Medicine, Radiation Oncology, University of Arizona Cancer Center, Tucson, AZ, USA

    Anne E. Cress

Authors
  1. Amit M. Algotar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Suzanne Stratton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William L. Harryman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne E. Cress
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amit M. Algotar .

Editor information

Editors and Affiliations

  1. Arizona Cancer Center, University of Arizona College of Medicine, Tucson, Arizona, USA

    David Alberts

  2. Department of Obstetrics and Gynecology, Indiana University Schools of Medicine and Public Health, Indianapolis, Arizona, USA

    Lisa M. Hess

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Algotar, A.M., Stratton, M.S., Harryman, W.L., Cress, A.E. (2014). Prevention of Prostate Cancer. In: Alberts, D., Hess, L. (eds) Fundamentals of Cancer Prevention. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38983-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-38983-2_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-38982-5

  • Online ISBN: 978-3-642-38983-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation